ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TBET Tibet Pharmaceuticals Inc (CE)

0.000001
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tibet Pharmaceuticals Inc (CE) USOTC:TBET OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

Pomerantz Law Firm Has Filed a Class Action Against Tibet Pharmaceuticals, Inc. - TBET

08/06/2012 10:26pm

GlobeNewswire Inc.


Tibet Pharmaceuticals (CE) (USOTC:TBET)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Tibet Pharmaceuticals (CE) Charts.

Pomerantz Haudek Grossman & Gross LLP has filed a federal securities class action (12 Civ. 4511) in United States District Court, Southern District of New York, on behalf of all persons who purchased Tibet Pharmaceuticals, Inc. ("Tibet") (Other OTC:TBET) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus, declared effective by the SEC on December 28, 2010, issued in connection with the Company's Initial Public Offering (the "IPO"), including all those who purchased Tibet stock after December 28, 2010. The action seeks to recover damages caused by defendants' violations of federal securities laws and to pursue remedies under the Securities Act of 1933.

If you are a shareholder who purchased Tibet securities during the Class Period, you have until July 25, 2012 to ask the Court to appoint you as lead plaintiff for the class. A copy of the complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Rachelle R. Boyle at rrboyle@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Tibet is a specialty pharmaceutical company focusing on the research, development, manufacturing and marketing of modernized traditional Tibetan medicines. The Complaint alleges that Tibet's registration statement and prospectus contained misstatements of material fact because at the time of the IPO, the Company misstated its true financial condition. Contrary to the representations made in the registration statement and prospectus, Tibet actually had internal control deficiencies that would have a materially adverse effect on its operations and financial reporting. 

On June 10, 2011, the Company's Chief Executive Officer inexplicably resigned from the Company. On September 6, 2011, the Company's auditor, Acquavella, Chiarelli, Shuster, Berkower & Co., LLP resigned.

On April 3, 2012, the NASDAQ halted trading of Tibet's stock for "additional information requested." When the trading resumed on April 27, 2012 on the Pink Sheets, Tibet's shares plummeted $0.94 or nearly 73%, to close at $0.35.

The Pomerantz Firm, with offices in New York and Chicago, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.

CONTACT: Rachelle R. Boyle
         Pomerantz Haudek Grossman & Gross LLP
         rrboyle@pomlaw.com

1 Year Tibet Pharmaceuticals (CE) Chart

1 Year Tibet Pharmaceuticals (CE) Chart

1 Month Tibet Pharmaceuticals (CE) Chart

1 Month Tibet Pharmaceuticals (CE) Chart

Your Recent History

Delayed Upgrade Clock